Human Metapneumovirus: Why it’s taken more than two decades to develop a vaccine
HMPV cases rise in China, concerns have emerged about the virus’ continued threat and the lack of targeted treatments.
ET Year-end Special Reads
Stocks to buy in 2025: 66 ideas from top brokerages for your new year portfolio
What does 2025 hold for India's IT services sector?
2025 may be the year of EVs in India, dominated by SUV launches
Also Read: China’s HMPV: How prepared is India for a new viral pandemic?
What is Human Metapneumovirus (HMPV)?
HMPV belongs to the Pneumoviridae family and the Metapneumovirus genus, and is an enveloped, single-stranded, negative-sense RNA virus, according to the Chinese Centre for Disease Control and Prevention (China CDC). It was first discovered by Dutch scientists who identified it in nasopharyngeal aspirates from children suffering from respiratory infections. Though identified more than 20 years ago, HMPV has been circulating globally for at least 60 years and continues to cause significant health concerns.
Despite its long-known presence, there is no antiviral medication to treat HMPV. Cleveland Clinic, a prominent medical centre, explains that while supportive therapies such as oxygen, IV fluids, and corticosteroids may help severe cases, hospitalisation is often required for those at risk of complications. The China CDC has similarly stated that there is no specific vaccine for HMPV and recommended preventative measures like mask-wearing in crowded places and regular hand washing to avoid transmission.
Also Read: Amid reports of HMPV outbreak in China, doctors warn of 11
